Pharmafile Logo

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Living with Crohn’s Disease (CD) covers 4EU+UK and Japan. Living with Psoriasis (PsO) covers the 4EU+UK. Living with Idiopathic Pulmonary Fibrosis (IPF) & Progressive Fibrosing Interstitial Lung Disease (PF-ILD) covers the US, 4EU+UK and China.

These new syndicated reports are based on quantitative and qualitative market research with patients and are available to purchase. The methodologies for all reports consist of 30-minute online interviews and 40-minute qualitative tele-depth interviews with patients, including a patient-diary exercise.

The reports are designed to provide an in-depth understanding of the patient journey, from diagnosis through to ongoing management of the condition. Through these reports, you will understand how patients’ lives are impacted physically and emotionally, what impacts treatment decision-making and satisfaction, and what unmet needs patients have related to their condition.

The Living With team at Research Partnership is continually expanding the reports to cover a large range of therapy areas and markets. To find out more about other upcoming reports, request an information pack, or arrange a meeting to discuss therapy areas of interest please contact us now.

Head of Living With, Mariel Metcalfe commented, “Research Partnership is committed to producing research which focuses on the voice of the patient, and to offer a more patient-centric view of what it is like to live with a long-term, life-changing illness. Our reports cover a wide range of therapy areas from Autoimmune, Dermatology, Gastroenterology and Respiratory, and we hope to expand the list of therapy areas year on year.”

Find out more about our Living With reports here

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

How DataGateway unified oncology data for real-world insights & market intelligence

Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

Preparing for ASH 2025: Pharma’s role in hematology innovation

As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

AI without limits: A smarter, integrated approach to Medical Affairs

At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

AI with intent: How Inizio is redefining pharma through precision and partnership

At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.